SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
---------------------------
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
March 23, 2000 (March 10, 2000)
Date of Report (Date of earliest event reported)
AVAX TECHNOLOGIES, INC.
(Exact name of Registrant as specified in its charter)
Delaware 000-29222 13-3575874
(State or other jurisdiction (Commission File Number) (IRS Employer
of incorporation) Identification Number)
4520 Main Street
Suite 930
Kansas City, MO 64111
(Address of principal executive offices)
(816) 960-1333
(Registrant's telephone number, including area code)
<PAGE>
Item 5. Other Events
$25.1 Million Institutional Private Placement
On March 10, 2000, the Company completed an approximately $25.1 million
private placement of its common stock, $.004 par value, and related warrants
with institutional investors. Gruntal & Co., L.L.C. acted as the placement agent
for the offering.
The private placement consisted of 2,259,494 newly issued shares of common
stock at the purchase price of $11.125 per share, and warrants to purchase an
additional 225,952 shares of common stock. The warrant exercise price is $12.79
per share of common stock, or 115% of the offering price of the common stock.
The warrants will expire on March 10, 2005.
Net proceeds from the private placement are approximately $24.2 million
and will be used for working capital.
Item 7. Financial Statements and Exhibits.
1. December 31, 1999 Pro-Forma Balance Sheet to include proceeds from
the private placement.
Exhibits.
4.1 Form of Series 2000 Warrant.
10.1 Securities Purchase Agreement dated March 7, 2000.
99.1 Press Release dated March 13, 2000.
2
<PAGE>
AVAX Technologies, Inc.
Pro-Forma Balance Sheet
December 31, 1999
Unaudited
<TABLE>
<CAPTION>
Pro-Forma
(A) (B) Balance Sheet
December 31, March 10, 2000 December 31,
1999 Stock Issuance 1999
<S> <C> <C> <C>
Current assets
Cash and cash equivalents $ 3,426,059 $ 24,314,770 $ 27,740,829
Marketable securities 8,868,621 8,868,621
Prepaid expenses and other assets 336,821 336,821
-------------------------------------------
Total current assets 12,631,501 24,314,770 36,946,271
Property, plant and equipment, at cost 2,458,678 2,458,678
Less: accumulated depreciation 116,862 116,862
-------------------------------------------
Net property, plant and equipment 2,341,816 -- 2,341,816
-------------------------------------------
Total assets $ 14,973,317 $ 24,314,770 $ 39,288,087
===========================================
Current liabilities
Accounts payable and accrued liabilities $ 401,263 $ -- $ 401,263
-------------------------------------------
Total current liabilities 401,263 -- 401,263
Minority interest in consolidated
subsidiaries 502,341 -- 502,341
Shareholder's equity
Series B convertible preferred stock 739 -- 739
Series C convertible preferred stock 1,013 -- 1,013
Common stock 44,311 9,038 53,349
Additional paid in capital 35,406,036 24,305,732 59,711,768
Subscription receivable (422) -- (422)
Deferred compensation (156,124) -- (156,124)
Deficit accumulated during the
development stage (21,225,840) -- (21,225,840)
-------------------------------------------
Total shareholder's equity 14,069,713 24,314,770 38,384,483
-------------------------------------------
Total liabilities and shareholder's equity $ 14,973,317 $ 24,314,770 $ 39,288,087
===========================================
</TABLE>
Notes to Pro-Forma Balance Sheet:
Note A: These numbers were derived from the Company's December 31, 1999 audited
financial statements
Note B: This column represents the adjustment to the December 31, 1999
financial statements as if the financing completed on March 10, 2000
was completed as of December 31, 1999. The financing, which was a
private placement of common stock, included the issuance of 2,259,494
shares of the Company's common stock in exchange for gross proceeds of
$25,136,871. Netted against gross proceeds were commissions, expenses
and legal fees of $822,101.
3
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
AVAX TECHNOLOGIES, INC.
Date: March 23, 2000
By: /s/ Jeffrey M. Jonas
----------------------------------------
Name: Jeffrey M. Jonas, M.D.
Title: President and Chief Executive Officer
4
<PAGE>
Exhibit Index
Exhibit Number Description
-------------- -----------
4.1 Form of Series 2000 Warrant.
10.1 Securities Purchase Agreement dated March 7, 2000.
99.1 Press Release dated March 13, 2000.
5
Exhibit 4.1
Form of Warrant
THE WARRANT REPRESENTED BY THIS CERTIFICATE AND THE SECURITIES ISSUABLE UPON
EXERCISE THEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 OR
THE SECURITIES LAWS OF ANY STATE. NEITHER THE WARRANT NOR SUCH SECURITIES MAY BE
SOLD, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED WITHOUT SUCH REGISTRATION,
EXCEPT UPON DELIVERY TO THE COMPANY OF SUCH EVIDENCE AS MAY BE SATISFACTORY TO
COUNSEL FOR THE COMPANY TO THE EFFECT THAT ANY SUCH TRANSFER IS NOT IN VIOLATION
OF THE SECURITIES ACT OF 1933 OR APPLICABLE STATE SECURITIES LAWS OR ANY RULE OR
REGULATION PROMULGATED THEREUNDER.
AVAX TECHNOLOGIES, INC.
Series 2000 Warrant for the Purchase
of Shares of Common Stock
No. GW - ___ Delaware, U.S.A.
FOR VALUE RECEIVED, AVAX TECHNOLOGIES, INC., a Delaware corporation (the
"Company"), hereby certifies that ___________ (the "Holder"), its designee or
its permitted assigns is entitled to purchase from the Company, at any time or
from time to time commencing on March 10, 2000 and prior to 5:00 P.M., New York
City time, on March 10, 2005, up to ___________ (___________) fully paid and
non-assessable shares of common stock (subject to adjustment), $.004 par value
per share, of the Company for $12.79 per share (subject to adjustment) at an
aggregate purchase price of $[_________]. This Warrant, all similar Warrants
issued in accordance with the Purchase Agreement referred to herein, and all
warrants hereafter issued in exchange or substitution for this Warrant or
similar Warrants are referred to as the "Warrants;" common stock, $.004 par
value per share, of the Company, is referred to as the "Common Stock;" the
shares of the Common Stock purchasable hereunder or under any other Warrant (as
hereinafter defined) are referred to as the "Warrant Shares;" the aggregate
purchase price payable for the Warrant Shares purchasable hereunder is referred
to as the "Aggregate Warrant Price;" the price payable (initially $12.79 per
share, subject to adjustment) for each of the Warrant Shares is referred to as
the "Per Share Warrant Price;" the holder of this Warrant is referred to as the
"Holder;" the holder of this Warrant and all other Warrants and Warrant Shares
are referred to as the "Holders;" and Holders of more than 50% of the
outstanding Warrants are referred to as the "Majority of the Holders"). The
Aggregate Warrant Price is not subject to adjustment.
This Warrant, together with Warrants of like tenor, constituting in the
aggregate Warrants to purchase __________ Warrant Shares, was originally issued
pursuant to a Securities Purchase Agreement dated as of March 7, 2000 (the
"Purchase Agreement") among the Company and the purchasers named therein. By
acceptance of this Warrant, the Holder agrees to comply with all applicable
provisions of the Purchase Agreement to the same extent as if it were a party
thereto.
-1-
<PAGE>
1. Exercise of Warrant. (a) This Warrant may be exercised in whole at any
time, or in part from time to time, commencing on March 10, 2000 and prior to
5:00 P.M., New York City time, on March 10, 2005 by the Holder by the surrender
of this Warrant (with the subscription form at the end hereof duly executed) at
the address set forth in Section 9(a), together with proper payment of the
Aggregate Warrant Price, or the proportionate part thereof if this Warrant is
exercised in part, with payment for the Warrant Shares made by certified or
official bank check payable to the order of the Company; or
(b) If this Warrant is exercised in part, this Warrant must be exercised
for a number of whole shares of the Common Stock and the Holder is entitled to
receive a new Warrant covering the Warrant Shares that have not been exercised
and setting forth the proportionate part of the Aggregate Warrant Price
applicable to such Warrant Shares.
(c) Upon surrender of this Warrant, the Company will (i) issue a
certificate or certificates in the name of the Holder for the number of whole
shares of the Common Stock to which the Holder is entitled and, if this Warrant
is exercised in whole, in lieu of any fractional share of the Common Stock to
which the Holder may be entitled, pay to the Holder cash in an amount equal to
the fair value of the fractional share (determined in such reasonable manner as
the Board of Directors of the Company determines), and (ii) to the extent
applicable, deliver the other securities and properties receivable upon the
exercise of this Warrant, or the proportionate part thereof if this Warrant is
exercised in part, pursuant to the provisions of this Warrant.
2. Reservation of Warrant Shares; Listing. The Company agrees that, prior
to the expiration of this Warrant, the Company shall at all times (i) have
authorized and in reserve, and shall keep available, solely for issuance and
delivery upon the exercise of this Warrant, the shares of the Common Stock and
other securities and properties as from time to time shall be receivable upon
the exercise of this Warrant, free and clear of all restrictions on sale or
transfer, other than under Federal or state securities laws, and free and clear
of all preemptive rights and rights of first refusal and (ii) use its best
efforts to keep the Warrant Shares authorized for listing on the Nasdaq National
Market, the Nasdaq SmallCap Market or any national securities exchange on which
the Company's Common Stock is traded.
3. Protection Against Dilution. (a) If the Company hereafter (i) pays a
dividend or makes a distribution on its Common Stock in shares of Common Stock,
(ii) subdivides its outstanding shares of Common Stock into a greater number of
shares, (iii) combines its outstanding shares of Common Stock into a smaller
number of shares or (iv) issues by reclassification of its Common Stock any
shares of capital stock of the Company, then (x) the Per Share Warrant Price
(but not the Aggregate Warrant Price) and (y) the number of Warrant Shares
issuable hereunder (collectively the "Exercise Terms") shall be adjusted so that
the Holder upon the exercise hereof will be entitled to receive the number of
shares of Common Stock or other capital stock of the Company that the Holder
would have owned immediately following such action had the Warrant been
exercised immediately prior thereto. An adjustment made pursuant to this Section
3(a) will become effective immediately after the record date in the case of a
dividend or distribution and will become effective immediately after the
effective date in the case of a subdivision, combination or reclassification. If
the Board of Directors of the Company declares any dividend or distribution or
resolve to take any action referred to in this Section 3(a), it shall provide
written notice thereof to the Holders not less than 10 days prior to the record
date fixed for determining the stockholders entitled to participate therein.
(b) In the case of any capital reorganization or reclassification, or any
consolidation or merger to which the Company is a party, other than a merger or
consolidation in which the Company
-2-
<PAGE>
is the continuing corporation, or in the case of any sale or conveyance to
another entity of the property of the Company as an entirety or substantially as
an entirety, or in the case of any statutory exchange of securities with another
corporation (including any exchange effected in connection with a merger of a
third corporation into the Company), the Holder will have the right thereafter
to receive on the exercise of the Warrant the kind and amount of securities,
cash or other property that the Holder would have owned or have been entitled to
receive immediately after such reorganization, reclassification, consolidation,
merger, statutory exchange, sale or conveyance had the Warrant been exercised
immediately prior to the effective date of the reorganization, reclassification
consolidation, merger, statutory exchange, sale or conveyance and in any such
case, if necessary, appropriate adjustment shall be made in the application of
the provisions set forth in this Section 3 with respect to the rights and
interests thereafter of the Holder to the end that the provisions set forth in
this Section 3 shall thereafter correspondingly be made applicable, as nearly as
may reasonably be, in relation to any shares of stock or other securities
thereafter deliverable on the exercise of the Warrant. Notice of any such
reorganization, reclassification, consolidation, merger, exchange, sale or
conveyance shall be mailed to the Holders not less than 30 days prior to such
event. The above provisions of this Section 3(b) shall similarly apply to
successive reorganizations, reclassifications, consolidations, mergers,
statutory exchanges, sales or conveyances. The Company shall require the issuer
of any shares of stock or other securities or property thereafter deliverable on
the exercise of the Warrants to be responsible for all of the agreements and
obligations of the Company hereunder.
(c) If the Company issues rights, options, warrants or convertible
securities to all holders of its Common Stock, without any charge to or
consideration from such holders, entitling them to subscribe for or purchase
Common Stock at a price per share that is lower at the record date mentioned
below than the closing bid price (as defined below) for the trading day
immediately prior to such record date (the "Current Market Price"), then the Per
Share Warrant Price shall be determined by multiplying the Per Share Warrant
Price then in effect by a fraction, of which the numerator is the number of
shares of Common Stock outstanding immediately prior to the issuance of such
rights, options, warrants or convertible securities plus the number of
additional shares of Common Stock offered for subscription or purchase, and of
which the denominator is the number of shares of Common Stock outstanding
immediately prior to the issuance of such rights, options, warrants or
convertible securities plus the number of shares which the aggregate offering
price of the total number of shares offered would purchase at such Current
Market Price. Such adjustment shall be made whenever such rights, options,
warrants or convertible securities are issued, and shall become effective
immediately and retroactive to the record date for the determination of
stockholders entitled to receive such rights, options, warrants or convertible
securities.
The "closing bid price" for each trading day shall be the reported closing
bid price on the NASDAQ SmallCap Market or the NASDAQ National Market System
("NMS") (such markets are collectively referred to as "NASDAQ") or, if the
Common Stock is not quoted on NASDAQ, on the principal national securities
exchange on which common stock is listed or admitted to trading (based on the
aggregate dollar value of all securities listed or admitted to trading) or, if
not listed or admitted to trading on any national securities exchange or quoted
on NASDAQ, the closing bid price in the over-the-counter market as furnished by
any NASD member firm selected from time to time by the Company for that purpose,
or, if such prices are not available, the fair market value set by, or in a
manner established by, the Board of Directors of the Company in good faith.
"Trading day" shall mean a day on which the national securities exchange or
NASDAQ used to determine the closing bid price is open for the transaction of
business or the reporting of trades or, if the closing bid price is not so
determined, a day on which NASDAQ is open for the transaction of business.
-3-
<PAGE>
(d) If the Company distributes (other than a distribution in liquidation
of the Company) to all holders of its Common Stock, without any charge to or
consideration from such holder, evidences of its indebtedness or assets
(excluding cash dividends or distributions out of earnings), then in each case
the Company shall simultaneously distribute such evidences of its indebtedness
or assets pro rata to the Holders of Warrants on the record date or date of
effectiveness, as the case may be, fixed for determining the holders of Common
Stock entitled to participate in such distribution in an amount equal to the
amount that such Holders would have been entitled to receive had their Warrants
been exercised for shares of Common Stock immediately prior to the time for
determination of the holders of Common Stock entitled to participate in that
distribution.
(e) No adjustments in the Exercise Terms shall be required:
(i) Unless such adjustment would require an increase or decrease of
at least $0.05 per share of Common Stock; provided, however, that any
adjustments that by reason of this Section 3(e)(i) are not required to be
made shall be carried forward and cumulated with amounts in any subsequent
adjustment, and provided, further, however, that adjustments shall be
required and made in accordance with the provisions of this Section 3
(other than this Section 3(e)(i)) not later than such time as may be
required in order to preserve the tax-free nature of a distribution to the
Holder of this Warrant or Common Stock issuable upon the exercise hereof.
All calculations that shall be required pursuant to this Section 3 shall
be made to the nearest cent or to the nearest one-hundredth of a share, as
the case may be. Anything in this Section 3 to the contrary
notwithstanding, the Company shall be entitled to make such adjustments to
the Exercise Terms, in addition to those required by this Section 3 as it
in its discretion shall deem to be advisable in order that any stock
dividend, subdivision of shares or distribution of rights to purchase
stock or securities convertible or exchangeable for stock hereafter made
by the Company to its stockholders is not taxable;
(ii) If the Company issues shares of Common Stock pursuant to (a)
the exercise of any warrants (or warrants or options to acquire any shares
of convertible preferred stock) of the Company outstanding on the date
hereof, (b) the exercise of the Warrants, or a portion thereof, (c) the
conversion of shares of any series of convertible preferred stock of the
Company outstanding on the date hereof, (d) the exercise of any stock
options or warrants currently outstanding or issued after the date hereof
pursuant to any Company benefit plan or compensation arrangement, or (e)
the exercise of any warrants issued to Gruntal & Co. LLC in connection
with the transactions contemplated by the Purchase Agreement.
(f) Whenever the conversion rate is adjusted as provided in any provision
of this Section 3:
(i) the Company shall compute (or at the request of a Majority
of Holders shall retain a firm of independent public accountants (which may be
any such firm regularly employed by the Company) to compute) the adjusted
Exercise Terms in accordance with this Section 3 and shall prepare a certificate
signed by the principal financial officer of the Company (or cause any such
independent public accountants to execute a certificate) setting forth the
adjusted conversion rate and showing in reasonable detail the facts upon which
such adjustment is based, and such certificate shall forthwith be filed with the
registrar of the Warrant; and
(ii) the Company shall mail as soon as practicable after an
adjustment is required a notice stating that the Exercise Terms have been
adjusted and setting forth the adjusted Exercise Terms to all record holders of
Warrants at their last addresses as they shall appear in the records of the
Company.
-4-
<PAGE>
4. Fully Paid Stock; Taxes. The shares of the Common Stock represented by
each certificate for Warrant Shares delivered on the exercise of this Warrant
shall at the time of such delivery, be duly authorized, validly issued and
outstanding, fully paid and nonassessable, and not subject to preemptive rights
or rights of first refusal, and the Company will take all such actions as may be
necessary to assure that the par value, if any, per share of the Common Stock is
at all times equal to or less than the then Per Share Warrant Price. The Company
shall pay all documentary, stamp or similar taxes and other similar governmental
charges that may be imposed with respect to the issuance or delivery of any
shares of Common Stock upon exercise of the Warrant (other than income taxes);
provided, however, that if the shares of Common Stock are to be delivered in a
name other than the name of the Holder, no such delivery shall be made unless
the person requesting the same has paid to the Company the amount of transfer
taxes or charges incident thereto, if any.
5. Registration Under Securities Act of 1933. (a) The Holder shall have
the right to participate in the registration rights granted to Holders of
Registrable Securities (as defined in the Purchase Agreement) with respect to
the Warrant Shares, pursuant to Section 7 of the Purchase Agreement. By
acceptance of this Warrant, the Holder agrees to comply with the provisions of
Section 7 of the Purchase Agreement to the same extent as if it were a party
thereto.
(b) Until all of the Warrant Shares have been sold under a registration
statement declared effective by the Securities and Exchange Commission or
pursuant to Rule 144, the Company shall use its reasonable best efforts to file
with the Securities and Exchange Commission all current reports and the
information as may be necessary to enable the Holder to effect sales of its
shares in reliance upon Rule 144 promulgated under the Securities Act of 1933,
as amended (the "Act").
6. Investment Intent; Limited Transferability. (a) The Holder represents,
by accepting this Warrant, that it understands that this Warrant and any
securities obtainable upon exercise of this Warrant have not been registered for
sale under Federal or state securities laws and are being offered and sold to
the Holder pursuant to one or more exemptions from the registration requirements
of such securities laws. In the absence of an effective registration of such
securities or an exemption therefrom, any certificates for such securities shall
bear the legend set forth on the first page hereof. The Holder understands that
it must bear the economic risk of its investment in this Warrant and any
securities obtainable upon exercise of this Warrant for an indefinite period of
time, as this Warrant and such securities have not been registered under Federal
or state securities laws and therefore cannot be sold unless subsequently
registered under such laws, unless an exemption from such registration is
available.
(b) The Holder, by its acceptance of this Warrant, represents to the
Company that it is acquiring this Warrant and will acquire any securities
obtainable upon exercise of this Warrant for its own account for investment and
not with a view to, or for sale in connection with, any distribution thereof in
violation of the Act. The Holder agrees that this Warrant and any such
securities will not be sold or otherwise transferred unless (i) a registration
statement with respect to such transfer is effective under the Act and any
applicable state securities laws or (ii) such sale or transfer is made pursuant
to one or more exemptions from the Act.
(c) This Warrant may not be sold, transferred, assigned or hypothecated by
the Holder except in compliance with the provisions of the Act and the
applicable state securities "blue sky" laws, and is transferable only upon the
books of the Company, which it shall cause to be maintained for such purpose.
The Company may treat the registered Holder of this Warrant as he, she or it
appears on the Company's books at any time as the Holder for all purposes. The
Company shall permit any Holder of a Warrant or his duly authorized attorney,
upon written request during ordinary business hours, to inspect and copy or make
extracts from its books showing the registered holders of Warrants. All Warrants
issued upon the
-5-
<PAGE>
transfer or assignment of this Warrant will be dated the same date as this
Warrant, and all rights of the holder thereof shall be identical to those of the
Holder.
7. Loss, etc., of Warrant. Upon receipt of evidence satisfactory to the
Company of the loss, theft, destruction or mutilation of this Warrant, and of
indemnity reasonably satisfactory to the Company, if lost, stolen or destroyed,
and upon surrender and cancellation of this Warrant, if mutilated, the Company
shall execute and deliver to the Holder a new Warrant of like date, tenor and
denomination.
8. Warrant Holder Not Stockholder. This Warrant does not confer upon the
Holder any right to vote on or consent to or receive notice as a stockholder of
the Company, as such, in respect of any matters whatsoever, nor any other rights
or liabilities as a stockholder, prior to the exercise hereof; this Warrant
does, however, require certain notices to Holders as set forth herein.
9. Communication. Any notice or other communication shall be effective and
shall be deemed to have been given if, the same is in writing and is mailed by
first-class mail, postage prepaid, addressed to:
(a) the Company at AVAX Technologies, Inc.,4520 Main Street, Suite 930,
Kansas City, MO 64111, Attn: Jeffrey M. Jonas, M.D., President and Chief
Executive Officer, or such other address as the Company has designated in
writing to the Holder, or
(b) the Holder at [INSERT ADDRESS] or other such address as the Holder has
designated in writing to the Company.
10. Headings. The headings of this Warrant have been inserted as a matter
of convenience and shall not affect the construction hereof.
11. Applicable Law. This Warrant shall be governed by and construed in
accordance with the laws of the State of Delaware without giving effect to the
principles of conflicts of law thereof.
[Remainder of page left blank intentionally.]
-6-
<PAGE>
12. Amendment, Waiver, etc. Except as expressly provided herein, neither
this Warrant nor any term hereof may be amended, waived, discharged or
terminated other than by a written instrument signed by the party against whom
enforcement of any such amendment, waiver, discharge or termination is sought;
provided, however, that any provisions hereof may be amended, waived, discharged
or terminated upon the written consent of the Company and the Majority of the
Holders.
IN WITNESS WHEREOF, the Company has caused this Warrant to be signed by
its President and attested by its Secretary this 10th day of March, 2000.
AVAX TECHNOLOGIES, INC.
By:_____________________________________
Name: Jeffrey M. Jonas, M.D.
Title: President and Chief Executive Officer
ATTEST:
___________________________
Secretary
-7-
<PAGE>
EXERCISE OF WARRANT
The undersigned, ___________________, pursuant to the provisions of the
foregoing Warrant, hereby elects to purchase ____________________ shares of the
Common Stock, par value $.004 per share, of AVAX Technologies, Inc. covered by
said Warrant, and makes payment therefor in full at the Per Share Warrant Price
provided in the Warrant.
Dated:_______________ Signature:___________________________
Address:_____________________________
ASSIGNMENT
FOR VALUE RECEIVED, _______________ hereby sells, assigns and transfers
unto ____________________ the foregoing Warrant and all rights evidenced
thereby, and does irrevocably constitute and appoint _____________________,
attorney, to transfer said Warrant on the books of AVAX Technologies, Inc.
Dated:_______________ Signature:___________________________
Address:_____________________________
PARTIAL ASSIGNMENT
FOR VALUE RECEIVED, _______________ hereby assigns and transfers unto
____________________ the right to purchase _______ shares of Common Stock, par
value $.004 per share, of AVAX Technologies, Inc. covered by the foregoing
Warrant, and a proportionate part of said Warrant and the rights evidenced
thereby, and does irrevocably constitute and appoint ____________________,
attorney, to transfer such part of said Warrant on the books of the Company.
Dated:_______________ Signature:___________________________
Address:_____________________________
-1-
Exhibit 10.1
================================================================================
SECURITIES PURCHASE AGREEMENT
among
AVAX TECHNOLOGIES, INC.,
and
THE SEVERAL PURCHASERS NAMED IN EXHIBIT A
Dated as of March 7, 2000
================================================================================
-1-
<PAGE>
SECURITIES PURCHASE AGREEMENT
THIS SECURITIES PURCHASE AGREEMENT (this "Agreement") is dated as of March
7, 2000, among AVAX TECHNOLOGIES, INC., a Delaware corporation (the "Company"),
and the several PURCHASERS named in Exhibit A (individually a "Purchaser" and
collectively, the "Purchasers").
Recitals:
1. The Company desires to issue and sell to Purchasers, and Purchasers
desire to purchase from the Company, an aggregate of 2,260,000 shares (the
"Shares") of Common Stock, $.004 par value per share (the "Common Stock") upon
and subject to the terms and conditions of this Agreement.
2. To induce Purchasers to purchase the Shares, the Company will issue to
each of the Purchasers certain warrants (in the form attached as Exhibit B) to
purchase an aggregate of 226,000 shares of Common Stock at an exercise price of
$12.79 per share (the "Warrants"). Unless the context otherwise requires, the
term Shares includes any shares of Common Stock issuable upon exercise of the
Warrants (the "Conversion Shares").
Agreement:
The Company and Purchasers agree as follows:
Section 1. Purchase of Company Securities.
1.1. Purchase and Sale of the Shares and the Warrants. Subject to the
terms and conditions of this Agreement, the Company (i) will issue and sell to
Purchasers, and each Purchaser, severally and not jointly, will purchase from
the Company the number of Shares set forth on Exhibit A opposite Purchaser's
name at the purchase price set forth opposite each Purchaser's name on Exhibit A
("Purchase Price"), and (ii) will issue the number of Warrants set forth on
Exhibit A opposite Purchaser's name at no additional consideration.
Section 2. Closing. The closing (the "Closing") of the purchase and sale
of the Shares and the issuance of the Warrants (the "Offering") will take place
at the offices of Gilmore & Bell, P.C., 2405 Grand Boulevard, Suite 1100, Kansas
City, Missouri 64108, at 10:00 A.M., local time, on Friday, March 10, 2000. The
Closing may take place at another time, place or earlier date as is mutually
agreed upon by the Company and Purchasers. The date of the Closing is referred
to as the "Closing Date." At the Closing, the Company will issue to each
Purchaser (i) stock certificates representing the Shares and (ii) the Warrants
being purchased by Purchaser in accordance with Exhibit A, against payment of
each Purchaser's Purchase Price by wire transfer of immediately available United
States funds payable to the Company's account pursuant to the wire transfer
instructions set forth on Exhibit A. The Shares and the Warrants will be
registered in Purchasers' names or the names of the nominees of Purchasers
pursuant to instructions delivered to the Company not less than two business
days prior to the Closing Date and will be delivered to Purchasers within 10
business days after the Closing Date.
Section 3. Conditions to the Obligations of Purchasers at Closing. The
obligation of each Purchaser to purchase and pay for the Shares and Warrants at
Closing is subject to the satisfaction on or prior to the Closing Date of the
following conditions, each of which may be waived by Purchasers:
-2-
<PAGE>
3.1 Opinion of Counsel to the Company. The Purchasers will have received
from Gilmore & Bell, P.C., counsel for the Company, its opinion dated the
Closing Date in the form of Exhibit C.
3.2 Representations and Warranties. The representations and warranties of
the Company contained in Section 6 must be true and correct in all material
respects as of the Closing Date except to the extent that the representations
and warranties relate to an earlier date in which case the representations and
warranties must be true and correct in all material respects as of the earlier
date.
3.3 Performance of Covenants. The Company will have performed or complied
in all material respects with all covenants and agreements required to be
performed by it on or prior to the Closing pursuant to this Agreement.
3.4 No Injunctions; etc. No court or governmental injunction, order or
decree prohibiting the purchase and sale of the Shares and Warrants will be in
effect. There will not be in effect any law, rule or regulation prohibiting or
restricting the sale or requiring any consent or approval of any person that has
not been obtained to issue and sell the Shares and Warrants to Purchasers.
3.5 Closing Documents. The Company will have delivered to Purchasers the
following:
(a) a certificate of the Secretary of the Company, dated as of the Closing
Date, as to the continued existence of the Company, certifying (i) the attached
copies of the Certificate of Incorporation and By-laws of the Company, and (ii)
the resolutions of the Board of Directors of the Company authorizing the
execution, delivery and performance of this Agreement and the Warrants; and
(b) a certificate of the Secretary of State of the State of Delaware,
dated a recent date, to the effect that the Company is in good standing in the
State of Delaware and that all annual reports, if any, have been filed as
required and that all taxes and fees have been paid in connection therewith.
3.6 Waivers and Consents. The Company will have obtained all material
consents and waivers necessary to execute and deliver this Agreement and all
related documents and agreements and to issue and deliver the Shares and
Warrants, and all consents and waivers will be in full force and effect.
Section 4. Conditions to the Obligations of the Company at Closing. The
obligation of the Company to issue and sell the Shares and the Warrants to
Purchasers at Closing is subject to the satisfaction on or prior to the Closing
Date of the following conditions, each of which may be waived by the Company:
4.1 Representations and Warranties. The representations and warranties of
Purchasers contained in this Agreement must be true and correct in all material
respects as of the Closing Date.
4.2 No Injunctions. No court or governmental injunction, order or decree
prohibiting the purchase or sale of the Shares or Warrants will be in effect.
Section 5. Representations and Warranties of Purchasers. Each Purchaser,
severally and not jointly, represents and warrants to the Company that:
5.1 Accredited Investor. Purchaser is an "accredited investor" within the
meaning of Regulation D under the Securities Act of 1933, as amended (the
"Securities Act"). Purchaser is acquiring the Shares and Warrants for its own
account or for the account of its customers, each of whom is an "accredited
investor" and not with a present view to, or for sale in connection with, any
distribution thereof in violation of the registration requirements of the
Securities Act, without prejudice, however, to
-3-
<PAGE>
Purchaser's right, subject to the provisions of this Agreement, at all times to
sell or otherwise dispose of all or any part of the Shares and Warrants.
5.2 Authority, etc. Purchaser has the power and authority to execute and
deliver this Agreement and to perform its obligations hereunder and has obtained
all required consents, if any, for the execution and performance of this
Agreement by Purchaser. This Agreement, when executed and delivered by
Purchaser, will constitute a legal valid and binding obligation of Purchaser.
5.3 No Brokers. Other than Gruntal & Co., L.L.C. ("Gruntal") (as finder on
behalf of the Company only with respect to those Purchasers so indicated on
Exhibit A), no finder, broker, agent, financial person or other intermediary has
acted on behalf of Purchaser in connection with the purchase of the Shares or
Warrants by Purchaser or the consummation of this Agreement or any of the
transactions contemplated hereby. Purchaser has not had any direct or indirect
contact with any other investment banking firm (or similar firm) with respect to
the offer of the Shares or Warrants by the Company to Purchaser or Purchaser's
subscription for the Shares and Warrants.
5.4 Certain Trading Activity. Purchaser and its affiliates have not
directly or indirectly sold any shares of Common Stock since the earlier of (a)
the 20 trading days preceding the Closing Date or (b) the date on which
Purchaser entered into its Confidentiality Agreement with the Company. As of the
Closing Date, Purchaser does not directly or indirectly have a "short" position
and has not directly or indirectly entered into any hedging transaction with
respect to the Common Stock.
5.5 Ability to Bear Risks of Investment. Purchaser is able to bear the
economic risk of an investment in the Shares and Warrants and is able to afford
a complete loss of its investment.
5.6 Access to Information. Purchaser acknowledges that it has been
afforded (i) the opportunity to ask the questions it deemed necessary of, and to
receive answers from, representatives of the Company concerning the Company and
the terms and conditions of the Offering; and (ii) the opportunity to request
additional information concerning the Company as the Company possesses or can
acquire without unreasonable effort or expense.
5.7 No General Solicitation. Purchaser did not (i) receive or review any
advertisement, article, notice or other communication published in a newspaper
or magazine or similar media or broadcast over television or radio, whether
closed circuit, or generally available; or (ii) attend any seminar, meeting or
investor or other conference whose attendees were, to Purchaser's knowledge,
invited by any general solicitation or general advertising.
5.8 Investment Experience. Either by reason of Purchaser's business or
financial experience or the business or financial experience of its professional
advisors (who are unaffiliated with and are not compensated by the Company or
any affiliate, finder or selling agent of the Company, directly or indirectly),
Purchaser has the capacity to protect Purchaser's interests in connection with
the transactions contemplated by this Agreement.
5.9 Organization, Good Standing, etc. If Purchaser is an entity, it is a
corporation, limited liability company, trust or partnership or other similar
entity duly organized, validly existing and in good standing under the laws of
its jurisdiction. Purchaser has full power and authority (corporate or
otherwise) to execute and deliver this Agreement and to purchase the Shares and
Warrants. The execution and delivery by Purchaser of this Agreement and the
consummation of the transactions contemplated hereby have been duly authorized
by all necessary corporate or other action on the part of Purchaser. If
Purchaser is an individual, Purchaser has the legal capacity to enter into this
Agreement. This Agreement constitutes a legal, valid and binding obligation of
Purchaser, enforceable against Purchaser in accordance
-4-
<PAGE>
with its terms, subject to laws of general application relating to bankruptcy,
insolvency and the relief of debtors and rules of law governing specific
performance, injunctive relief or other equitable remedies, and to limitations
of public policy.
5.10 Due Authorization. If Purchaser is a corporation, limited liability
company, trust, partnership, employee benefit plan, individual retirement
account, Keogh Plan, or other tax-exempt entity, it is authorized and qualified
to become an investor in the Company on the terms and conditions set forth
herein and the person signing this Agreement on behalf of the entity has been
duly authorized by Purchaser to do so.
5.11 No Conflicts. No court or governmental injunction, order or decree
affecting Purchaser and prohibiting the execution and delivery by Purchaser of
this Agreement and the consummation of the transactions contemplated hereby is
in effect, and the terms of this Agreement do not conflict with the provision of
the Certificate or Articles of Incorporation or by-laws (or comparable charter,
partnership or other organizational documents) of Purchaser, or conflict with,
or result in a material breach or violation of, any of the terms or provisions
of, or constitute (with due notice or lapse of time or both) a material default
under, any material lease, loan agreement, mortgage, security agreement, trust
indenture or other agreement or instrument to which Purchaser is a party.
5.12 Consents, Approvals, etc. No material consent, approval, license,
permit, order or authorization of, or registration, declaration or filing with,
any court, administrative agency or commission or other governmental authority
or instrumentality, domestic or foreign, remains to be obtained or is otherwise
required to be obtained by Purchaser in connection with the authorization,
execution and delivery of this Agreement or the consummation of the transactions
contemplated hereby, including, without limitation the purchase and sale of the
Shares and Warrants.
Section 6. Representations and Warranties of the Company. The Company
represents and warrants to each Purchaser that:
6.1 Organization, Good Standing and Qualification. The Company is a
corporation duly organized, validly existing and in good standing under the laws
of the State of Delaware. The Company has full corporate power and authority to
own and hold its properties and to conduct its business. The Company is duly
licensed or qualified to do business, and in good standing, in each jurisdiction
in which the nature of its business requires licensing, qualification or good
standing, except for any failure to be so licensed or qualified or in good
standing that would not have a material adverse effect on the Company or its
results of operations, assets, or financial condition or on its ability to
perform its obligations under this Agreement, the Shares or the Warrants (a
"Material Adverse Effect"). Each direct or indirect subsidiary of the Company
and its state or country of organization is listed on Exhibit 21.1 to the
Company's Annual Report on Form 10-KSB for the year ended December 31, 1999 (the
"1999 10-KSB"). Each subsidiary is duly organized, validly existing and in good
standing under the laws of the jurisdiction of in which it was organized and has
full corporate power and authority to own and hold its properties and to conduct
its business.
6.2 Capitalization. As of the date hereof, the authorized capital stock of
the Company consists of 30,000,000 shares of Common Stock, par value $.004 per
share, and 5,000,000 shares of Preferred Stock, par value $0.01 per share, of
which (i) 300,000 shares are designated Series B Convertible Preferred Stock
(the "Series B Preferred Stock") and (ii) 120,000 shares are designated Series C
Convertible Preferred Stock ("Series C Preferred Stock"). As of March 7, 2000,
(i) 11,331,636 shares of Common Stock are issued and outstanding, (ii) 66,093
shares of Series B Preferred Stock are issued and outstanding, which are
convertible into 1,724,152 shares of Common Stock, (iii) 99,900 shares of Series
C Preferred Stock are issued and outstanding, which are convertible into
3,073,839 shares of
-5-
<PAGE>
Common Stock, (iv) 1,500,000 shares of Common Stock are reserved for issuance
upon exercise of outstanding options issued or issuable under the Company's 1992
Stock Option Plan (the "Option Plan"), (v) an aggregate of 1,284,802 shares of
Common Stock are reserved for issuance under stock options granted by the
Company outside the Option Plan, (vi) 658,950 shares of Common Stock were
reserved for issuance upon conversion of 25,259 shares of Series B Preferred
Stock issuable upon the exercise of outstanding warrants to acquire those shares
of Series B Preferred Stock, and (vii) an aggregate of 1,609,551 shares of
Common Stock were reserved for issuance under all other outstanding warrants. As
of the date hereof, the Company has elected to effect the mandatory conversion
of all outstanding shares of Series B Preferred Stock into an aggregate of
1,724,152 shares of Common Stock as of March 21, 2000. Thereafter, no shares of
Series B Preferred Stock will be deemed to be issued and outstanding (other than
the right to receive the conversion shares upon surrender of the Series B
Preferred Stock Certificates). Before giving effect to the transactions
contemplated by this Agreement, Schedule 6.2 sets forth a true and correct list
as of the Closing Date, of all outstanding options and warrants to purchase
directly or indirectly shares of Common Stock and Preferred Stock, the number of
options and warrants outstanding as of that date and the exercise price per
option or warrant. All the outstanding shares of Common Stock, Series B
Preferred Stock and Series C Preferred Stock have been duly authorized and
validly issued and are fully paid and nonassessable and free of preemptive
rights created by or through the Company. Except as set forth in this Section
6.2 or Schedule 6.2, there are no other options, warrants or other rights,
convertible debt, agreements, arrangements or commitments of any character
obligating the Company or any of its subsidiaries to issue or sell any shares of
capital stock of or other equity interests in the Company. The Company is not
obligated to retire, redeem, repurchase or otherwise reacquire any of its
capital stock or other securities.
6.3 Corporate Power, Authorization; Enforceability. The Company has full
corporate power and authority to execute, deliver and enter into this Agreement
and to consummate the transactions contemplated hereby. All action on the part
of the Company, its directors or stockholders necessary for the authorization,
execution, delivery and performance of this Agreement by the Company, the
authorization, sale, issuance and delivery of the Shares and Warrants
contemplated hereby and the performance of the Company's obligations hereunder
and thereunder has been taken. The Shares to be purchased on the Closing Date
have been duly authorized and, when issued in accordance with this Agreement,
will be validly issued, fully paid and nonassessable and will be free and clear
of all liens, adverse claims or encumbrances (collectively, "Liens") imposed by
or through the Company other than restrictions imposed by this Agreement and
applicable securities laws. The Warrants to be purchased on the Closing Date
have been duly authorized and, when issued in accordance with this Agreement,
will be validly issued and free and clear of all Liens imposed by or through the
Company other than restrictions imposed by this Agreement and applicable
securities laws. The Conversion Shares issuable upon the exercise of the
Warrants are and will, at all times until their issuance, be duly authorized and
reserved, and upon the exercise of the Warrants in accordance with the terms and
conditions thereof and this Agreement, will be validly issued, fully paid and
nonassessable shares of Common Stock and will be free and clear of all Liens
imposed by or through the Company other than restrictions imposed by this
Agreement and applicable securities laws. This Agreement has been duly executed
and delivered by the Company and constitutes a legal, valid and binding
obligation of the Company, enforceable against the Company in accordance with
its terms, subject to laws of general application relating to bankruptcy,
insolvency and the relief of debtors and rules of law governing specific
performance, injunctive relief or other equitable remedies, and to limitations
of public policy.
6.4 Financial Statements and SEC Documents. (a) Included in the 1999
10-KSB are true and complete copies of the audited balance sheet (the "Balance
Sheet") of the Company as of December 31, 1999, and the related audited
statements of operations, stockholders' equity (deficit) and cash flows for the
years ended December 31, 1998 and 1999 and for the period from January 12, 1990
(date of incorporation) to December 31, 1999 (the "Financial Statements"),
accompanied by the report of Ernst &
-6-
<PAGE>
Young LLP. The Financial Statements have been prepared in accordance with
generally accepted accounting principles, applied consistently with the past
practices of the Company (except as may be indicated in the notes thereto), and
as of their respective dates, fairly present, in all material respects, the
financial position of the Company and the results of its operations as of the
time and for the periods indicated therein.
(b) The Company has provided to each Purchaser the 1999 10-KSB. A
copy of each report, schedule, effective registration statement and definitive
proxy statement filed by the Company with the Securities and Exchange Commission
(the "SEC") since January 1, 1999, (as the documents may have been amended since
the time of their filing, the "SEC Documents") has also been made available to
each Purchaser via the SEC's EDGAR System. The Company has provided to each
Purchaser who has requested the same a true and complete copy of each SEC
Document that the Company was required to file since January 1, 1999. As of
their respective filing dates, each SEC Document complied in all material
respects with the requirements of the Securities Act or the Securities Exchange
Act of 1934, as amended (the "Exchange Act"), as applicable, and the rules and
regulations of the SEC thereunder applicable to the SEC Document, and no SEC
Document contained any untrue statement of a material fact or omitted to state
any material fact required to be stated therein or necessary to make the
statements therein, in light of the circumstances under which they were made,
not misleading. As of their respective filing dates, the financial statements of
the Company included in the SEC Documents complied as to form in all material
respects with then applicable accounting requirements and with the published
rules and regulations of the SEC with respect thereto, were prepared in
accordance with generally accepted accounting principles, applied consistently
with the past practices of the Company, and as of their respective dates, fairly
presented in all material respects the financial position of the Company and the
results of its operations as of the time and for the periods indicated therein
(except as may be indicated in the notes thereto or, in the case of the
unaudited statements, as permitted by Form 10-QSB, and Regulations S-B and S-X
of the SEC).
6.5 No Material Adverse Changes. Since December 31, 1999, except as
disclosed in the SEC Documents filed subsequent to that date, if any, there has
not been any material adverse change in the business, financial condition or
operating results of the Company except for changes that, individually or in the
aggregate, have not had or resulted in a Material Adverse Effect.
6.6 Absence of Certain Developments. Except as contemplated by this
Agreement, the SEC Documents or the Schedules hereto, since December 31, 1999,
through the date immediately preceding the Closing Date, the Company has not (a)
issued any stock, options, bond or other corporate security, (b) borrowed any
amount or incurred or became subject to any liabilities (absolute, accrued or
contingent), other than current liabilities incurred in the ordinary course of
business and liabilities under contracts entered into in the ordinary course of
business, (c) discharged or satisfied any lien or adverse claim or paid any
obligation or liability (absolute, accrued or contingent), other than current
liabilities shown on the Balance Sheet and current liabilities incurred in the
ordinary course of business; (d) declared or made any payment or distribution of
cash or other property to the stockholders of the Company or purchased or
redeemed any securities of the Company; (e) mortgaged, pledged or subjected to
any lien or adverse claim any of its properties or assets, except for liens for
taxes not yet due and payable or otherwise in the ordinary course of business;
(f) sold, assigned or transferred any of its assets, tangible or intangible,
except in the ordinary course of business or in an amount less than $250,000,
(g) suffered any extraordinary losses or waived any rights of material value
other than in the ordinary course of business; (h) made any capital expenditures
or commitments therefor other than in the ordinary course of business or in an
amount less than $250,000; (i) entered into any other transaction other than in
the ordinary course of business in an amount less than $250,000 or entered into
any material transaction, whether or not in the ordinary course of business; (j)
made any charitable contributions or pledges; (k) suffered any damages,
destruction or casualty loss, whether or not covered by insurance, affecting any
of the properties or assets
-7-
<PAGE>
of the Company or any other properties or assets of the Company which could,
individually or in the aggregate, have or result in a Material Adverse Effect;
(l) made any material change in the nature or operations of the business of the
Company; or (m) entered into any agreement or commitment to do any of the
foregoing.
6.7 No Conflict; Governmental Consents. (a) The execution and delivery by
the Company of this Agreement and the consummation of the transactions
contemplated hereby will not (i) result in the violation of any provision of the
Certificate of Incorporation or By-laws of the Company, (ii) result in any
violation of any law, statute, rule, regulation, order, writ, injunction,
judgment or decree of any court or governmental authority to or by which the
Company is bound, or (iii) conflict with, or result in a breach or violation of,
any of the terms or provisions of, or constitute (with due notice or lapse of
time or both) a default under, any lease, loan agreement, mortgage, security
agreement, trust indenture or other agreement to which the Company is a party or
by which it is bound or to which any of its properties or assets is subject, nor
result in the creation or imposition of any Lien upon any of the properties or
assets of the Company.
(b) No consent, approval, license, permit, order or authorization of, or
registration, declaration or filing with, any court, administrative agency or
commission or other governmental authority remains to be obtained or is
otherwise required to be obtained by the Company in connection with the
authorization, execution and delivery of this Agreement or the consummation of
the transactions contemplated hereby, including, without limitation the issue
and sale of the Shares and Warrants, except filings as may be required to be
made by the Company after the Closing with (i) the SEC, (ii) the National
Association of Securities Dealers, Inc. ("NASD"), (iii) the Nasdaq Stock Market,
Inc. and (iv) state blue sky or other securities regulatory authority.
6.8 Licenses. The Company has sufficient licenses, permits and other
governmental authorizations currently required for the conduct of its current
business and the ownership of its properties and is in all respects complying
therewith.
6.9 Litigation. Except as set forth in the Company's 1999 10-KSB, there
are no pending, or to the Company's knowledge, threatened, legal or governmental
proceedings against the Company.
6.10 Investment Company. The Company is not an "investment company" within
the meaning of that term under the Investment Company Act of 1940, as amended,
and the rules and regulations of the SEC thereunder.
6.11 No Default or Violation. The Company is not (i) in default under or
in violation of any indenture, loan or credit agreement or any other agreement
or instrument to which it is a party of by which it or any of its properties is
bound or (ii) in violation of any order of any court, arbitrator or governmental
body, except for any of the foregoing that is not reasonably expected to,
individually or in the aggregate, have or result in a Material Adverse Effect.
6.12 Listing and Maintenance Requirements Compliance. The Company has not
since January 1, 1998, received notice (written or oral) from any stock exchange
or market on which the Common Stock is or has been listed (or on which it has
been quoted) to the effect that the Company is not in compliance with the
continuing listing or maintenance requirements of the exchange or market.
6.13 Patents and Trademarks. Except as set forth in the Company's 1999
10-KSB, the Company has, or has rights to use, all patents, patent applications,
trademarks, trademark applications, service marks, trade names, copyrights and
licenses (collectively, the "Intellectual Property Rights") which are necessary
for use in connection with its business as presently conducted and which the
failure
-8-
<PAGE>
to have would have a Material Adverse Effect and to the Company's knowledge,
there is no existing infringement by another person or entity of any of the
Intellectual Property Rights which are necessary for use in connection with the
Company's business as presently conducted.
6.14 Environment Matters. The Company has obtained all permits, licenses
and other authorizations which are required under federal, state and local laws
relating to pollution or protection of the environment, including laws related
to emissions, discharges, releases or threatened releases of pollutants,
contaminants or hazardous or toxic material or wastes into ambient air, surface
water, ground water or land, or otherwise relating to the manufacture,
processing, distribution, use, treatment, storage, disposal, transport or
handling or pollutants, contaminants or hazardous or toxic materials or wastes
("Environmental Laws"), except for any failures to obtain the permits, licenses
or authorizations which would not, individually or in the aggregate, have or
result in a Material Adverse Effect. The Company is in compliance with all terms
and conditions of the required permits, licenses and authorizations and is also
in full compliance with all other limitations, restrictions, conditions and
requirements contained in the Environmental Laws or contained in any plan,
order, judgement, decree or notice, except for any non-compliance which could
not, individually or in the aggregate, have or result in a Material Adverse
Effect. The Company is not aware of, nor has the Company received notice of, any
events, conditions, circumstances, actions or plans which may interfere with or
prevent continued compliance or which would give rise to any liability under any
Environmental Laws, except for any liability which could not, individually or in
the aggregate, have or result in a Material Adverse Effect.
Section 7. Registration of Common Stock.
7.1. Registrable Securities. For the purposes of this Agreement,
"Registrable Securities" means (a) the Shares, (b) shares of Common Stock issued
or issuable upon exercise of the Warrants or (c) shares of Common Stock issued
as a distribution with respect to the shares referred to in (a) or (b) above;
provided that (i) any shares of Common Stock will cease to be Registrable
Securities, and (ii) the Company will not be obligated to maintain the
effectiveness of the Shelf Registration Statement (as defined below), and the
Company's obligations under this Section 7 will cease, with respect to a
holder's (a "Holder") Registrable Securities following the earlier of (x) the
second anniversary of the Closing Date and (y) the date on which the Company
delivers an opinion of counsel in form and substance reasonably satisfactory to
the Holder that (1) the Holder may sell in a single transaction all Registrable
Securities then held or issuable to the Holder on a registered securities
exchange or Nasdaq market under an applicable exemption from the registration
requirements of the Securities Act (pursuant to Rule 144 under the Securities
Act or otherwise) and (2) all transfer restrictions and restrictive legends with
respect to the Registrable Securities will be removed upon the consummation of
the sale. The period of time during which the Company is required to keep the
Shelf Registration Statement effective is referred to as the "Registration
Period."
7.2 Registration (a) The Company will as soon as practicable following the
Closing Date but not later than 30 days after the Closing Date (the "Filing
Period"), file with the SEC a shelf registration statement on Form S-3 or
successor form or another form selected by the Company that is available to it
under the Securities Act (the "Shelf Registration Statement") with respect to
the Registrable Securities beneficially owned by Purchasers following the
Closing. The Company may amend the Shelf Registration Statement from time to
time to register securities other than Registrable Securities for sale for the
account of any person or entity; provided, however, that the amendment will be
permitted only so long as the SEC rules provide that the amendment does not give
the SEC the right to review the Shelf Registration Statement.
(b) The Filing Period and the Effectiveness Period (as defined below) will
be extended by the number of days that (i) any delay is due to the failure of a
Holder to reasonably cooperate in providing to
-9-
<PAGE>
the Company the information requested by the Company in writing for use in
connection with the Shelf Registration Statement and (ii) the SEC does not
provide comments to the Company (or declare the Shelf Registration Statement
effective) within (A) 30 days after the initial filing of the Shelf Registration
Statement or (B) 7 days after the filing of any pre-effective amendment to the
Shelf Registration Statement, so long as the Company has responded promptly to
any comments pending at the time a pre-effective amendment to the Shelf
Registration Statement is filed.
7.3. Registration Procedures. In connection with the registration of any
Registrable Securities under the Securities Act as provided in this Section 7,
the Company will use its reasonable best efforts:
(a) To cause the Shelf Registration Statement (and any other related
registrations, qualifications or compliances as may be reasonably requested and
as would permit or facilitate that sale and distribution of all Registrable
Securities until the distribution thereof is complete) to become effective as
soon as practicable following the filing thereof but not later than 180 days
after the Closing Date (the "Effectiveness Period");
(b) Prepare and file with the SEC the amendments and supplements to the
Shelf Registration Statement and the prospectus used in connection therewith and
take all other actions as may be necessary to keep the Shelf Registration
Statement continuously effective until the disposition of all securities in
accordance with the intended methods of disposition by the Holder or Holders
thereof set forth in the Shelf Registration Statement will be completed, and to
comply with the provisions of the Securities Act (to the extent applicable to
the Company) with respect to the dispositions;
(c) Furnish to each Holder of Registrable Securities a reasonable number
of copies of the Shelf Registration Statement and of each amendment and
supplement thereto, a number of copies of the prospectus included in the Shelf
Registration Statement (including each preliminary prospectus), in conformity
with the requirements of the Securities Act, and the other documents (including
exhibits to any of the foregoing), as the Holder may reasonably request, in
order to facilitate the disposition of the Registrable Securities owned by
Holder;
(d) To register or qualify the Registrable Securities covered by the Shelf
Registration Statement under blue sky laws of the various states as any Holder
reasonably requests, and do any and all other acts and things that may be
reasonably necessary or advisable to enable a Holder to consummate the
disposition in the states the Registrable Securities owned by Holder, except
that the Company will not be required to qualify generally to do business as a
foreign corporation in any jurisdiction wherein it would not, but for the
requirements of this Section 7.3(d) be obligated to be qualified, to subject
itself to taxation in any the jurisdiction, or to consent to general service of
process in any the jurisdiction;
(e) Provide a transfer agent and registrar for the Registrable Securities
covered by the Shelf Registration Statement not later than the effective date of
the Shelf Registration Statement;
(f) Notify each Holder of Registrable Securities at any time when a
prospectus relating thereto is required to be delivered under the Securities
Act, of the happening of any event as a result of which the prospectus included
in the Shelf Registration Statement contains an untrue statement of a material
fact or omits any fact necessary to make the statements therein not misleading,
and, at the request of any Holder, the Company will promptly prepare a
supplement or amendment to the prospectus so that, as thereafter delivered to
the purchasers of Registrable Securities, the prospectus will not contain an
untrue statement of a material fact or omit to state any fact necessary to make
the statements therein not misleading;
-10-
<PAGE>
(g) Cause all Registrable Securities to be listed on each securities
exchange or automated over-the-counter trading system on which similar
securities issued by the Company are then listed;
(h) Enter into customary agreements (including, in the event the Holders
elect to engage an underwriter in connection with the Shelf Registration
Statement, an underwriting agreement containing customary terms and conditions)
and take all other actions as reasonably required in order to expedite or
facilitate the disposition of Registrable Securities; provided, however, that
the Company will not be liable for any expenses, including, without limitation,
any underwriter's fees, commissions and discounts;
(i) With a view to making available to the Holders the benefits of
certain rules and regulations of the SEC that at any time permit the sale of the
Registrable Securities to the public without registration, the Company agrees to
use its reasonable best efforts to:
(i) make and keep public information available, as those terms are
understood and defined in Rule 144 under the Securities Act;
(ii) file with the SEC in a timely manner all reports and other
documents required of the Company under the Exchange Act; and
(iii) so long as a Holder owns any unregistered Registrable
Securities, furnish to the Holder upon any reasonable request a written
statement by the Company as to its compliance with the public information
requirements of Rule 144 under the Securities Act, and of the Exchange
Act, a copy of the most recent annual or quarterly report of the Company,
and the other SEC reports and documents of the Company as the Holder may
reasonably request in availing itself of any rule or regulation of the SEC
allowing a Holder to sell any Registrable Securities without registration
(excluding any reports or documents of the Company that the Company, in
its sole discretion, deems confidential).
(j) Make every reasonable effort to obtain the withdrawal of any order
suspending the effectiveness of the Shelf Registration Statement at the earliest
possible time.
7.4 Registration and Selling Expenses. All expenses incurred by the
Company in connection with the Company's performance of or compliance with this
Section 7, including, without limitation, (i) all SEC registration and filing
fees, (ii) blue sky fees and expenses, (iii) all necessary printing and
duplicating expenses, and (iv) all fees and disbursements of counsel and
accountants retained on behalf of the Company (all expenses being called
"Registration Expenses"), will be paid by the Company. Each Holder may, at its
election, retain its own counsel and other representatives and advisors as it
chooses at its own expense.
7.5 No Delay. The Holders will have no right to take any action to
restrain, enjoin or otherwise delay any registration pursuant to Section 7.2
hereof as a result of any dispute, controversy or other matter that may arise
with respect to the interpretation or implementation of this Agreement.
7.6 Certain Obligations of Holders. (a) Each Holder agrees that, upon
receipt of any written request from the Company notifying the Holder of the
happening of any event requiring the preparation of a supplement or amendment to
the Shelf Registration Statement so that, as thereafter delivered to the
Holders, the prospectus will not contain an untrue statement of a material fact
or omit to state any material fact required to be stated therein or necessary to
make the statements therein not misleading and requesting that the Holder
discontinue disposition of Registrable Securities pursuant to the Shelf
Registration Statement, each Holder will forthwith discontinue disposition of
Registrable Securities pursuant to the Shelf Registration Statement until its
receipt of copies of the supplemented or amended
-11-
<PAGE>
effective prospectus from the Company and, if so directed by the Company, each
Holder will deliver to the Company all copies, other than permanent file copies
then in the Holder's possession, of the prospectus covering the Registrable
Securities current at the time of receipt of the notice.
(b) Each Holder agrees to suspend, upon written request of the Company,
any disposition of Registrable Securities pursuant to the Shelf Registration
Statement during (A) any period not to exceed one 90-day period within any one
12-month period the Company requires in connection with a primary public
offering of equity securities in which the Company will engage an underwriter
and (B) any period, not to exceed one 90-day period per 12-month period, when
the Company determines in good faith that offers and sales pursuant thereto
should not be made by reason of the presence of material undisclosed
circumstances or developments with respect to which the disclosure that would be
required in a prospectus is premature or would interfere with any material
financing, acquisition, merger, reorganization or other transaction involving
the Company, would have an adverse effect on the Company or is otherwise
inadvisable for the Company.
(c) As a condition to the inclusion of its Registrable Securities, each
Holder will furnish to the Company the information regarding the Holder and the
intended method of distribution of the securities as the Company may from time
to time request or as will be required in connection with any registration,
qualification or compliance referred to in this Section 7. Each Holder promptly
will furnish to the Company all information required to be disclosed in order to
make the information previously furnished to the Company not materially
misleading.
(d) Each Holder hereby covenants with the Company (1) not to make any sale
of the Registrable Securities without effectively causing the prospectus
delivery requirements under the Securities Act to be satisfied, and (2) if
Registrable Securities are to be sold by any method or in any transaction other
than on Nasdaq (or other national securities exchange), in the over-the-counter
market, in privately negotiated transactions, or in a combination of those
methods, to notify the Company at least five business days prior to the date on
which the Holder first offers to sell any Registrable Securities.
(e) Each Holder acknowledges and agrees that the Registrable Securities
sold pursuant to the Shelf Registration Statement are not transferable on the
books of the Company unless the stock certificate submitted to the transfer
agent evidencing the Registrable Securities is accompanied by a certificate
reasonably satisfactory to the Company to the effect that (A) the Registrable
Securities have been sold in accordance with this Agreement and the Shelf
Registration Statement and (B) the requirement of delivering a current
prospectus has been satisfied.
(f) Each Holder is hereby advised that the anti-manipulation provisions of
Regulation M under the Exchange Act may apply to sales of the Registrable
Securities offered pursuant to the Shelf Registration Statement, and agrees not
to take any action with respect to any distribution deemed to be made pursuant
to the Shelf Registration Statement, that constitutes a violation of Regulation
M under the Exchange Act or any other applicable rule, regulation or law.
(g) At the end of the Registration Period, the Holders of Registrable
Securities included in the Shelf Registration Statement will discontinue sales
of shares pursuant thereto upon receipt of notice from the Company of its
intention to remove from registration the shares covered thereby which remain
unsold, and the Holders promptly will notify the Company of the number of shares
registered that remain unsold immediately upon receipt of the notice from the
Company.
(h) The rights to cause the Company to register Registrable Securities
granted to the Holders by the Company under Section 7.2 may be assigned in whole
or in part by a Holder, provided, that: (i) the transfer may otherwise be
effected in accordance with applicable securities laws; (ii) the transfer
-12-
<PAGE>
involves not less than the lesser of all of the Holder's Registrable Securities
or 25,000 shares of Common Stock; (iii) the Holder gives prior written notice to
the Company; and (iv) the transferee agrees to comply with the terms and
provisions of this Agreement in a written instrument satisfactory in form and
substance to the Company and its counsel. Except as specifically permitted by
this Section 7.6, the rights of a Holder with respect to Registrable Securities
will not be transferable to any other person or entity, and any attempted
transfer will cause all rights of the Holder therein to be forfeited, void ab
initio and of no further force and effect.
(i) With the written consent of the Company and the Holders holding at
least 66 2/3% of the Registrable Securities that are then outstanding, any
provision of this Section 7 may be waived (either generally or in a particular
instance, either retroactively or prospectively and either for a specified
period of time or indefinitely) or amended. Upon the effectuation of each waiver
or amendment, the Company will promptly give written notice thereof to the
Holders, if any, who have not previously received notice thereof or consented
thereto in writing.
7.7 Indemnification. (a) The Company will indemnify, to the extent
permitted by law, each Holder of Registrable Securities and each person
controlling each Holder within the meaning of Section 15 of the Securities Act
against all losses, claims, damages, liabilities and expenses (or action in
respect thereof) including any of the foregoing incurred in settlement of any
litigation, commenced or threatened, arising out of or based on any untrue
statement or alleged untrue statement of a material fact contained in any
registration statement or prospectus (or any amendment or supplement thereto) or
any preliminary prospectus prepared in connection with the registration
contemplated by this Section 7, or based on any omission or alleged omission to
state therein a material fact required to be stated therein or necessary to make
the statements therein not misleading, and will reimburse each Holder and each
controlling person for reasonable legal and other expenses incurred in
connection with investigating or defending any claim, loss, damage, liability or
action as incurred, except insofar as the losses, claims, damages, liabilities
or expenses are caused by any untrue statement or alleged untrue statement or by
any omission or alleged omission made in reliance upon and in conformity with
written information furnished by any Holder and stated to be specifically for
use in the preparation of the registration statement or prospectus, provided the
Company will not be liable pursuant to this Section 7.7 if the losses, claims,
damages, liabilities or expenses have been caused by (i) any selling security
holder's failure to deliver a copy of the Shelf Registration Statement or
prospectus, or any amendments or supplements thereto at or prior to the time the
furnishing is required by the Securities Act or (ii) the failure by the Holder
to discontinue disposition of Registrable Securities pursuant to the Shelf
Registration Statement upon a written request from the Company in accordance
with Sections 7.6(a) or 7.6(b).
(b) In connection with any registration statement in which a Holder of
Registrable Securities is participating, each Holder will furnish to the Company
in writing the information as is reasonably requested by the Company for use in
any the registration statement or prospectus and will severally, but not
jointly, indemnify, to the extent permitted by law, the Company, its directors
and officers and each person or entity, if any, who controls the Company within
the meaning of Section 15 of the Securities Act, against any losses, claims,
damages, liabilities and expenses resulting from any untrue statement or alleged
untrue statement of a material fact or any omission or alleged omission of a
material fact required to be stated in the registration statement or prospectus
or any amendment thereof or supplement thereto or necessary to make the
statements therein not misleading, but only to the extent the losses, claims,
damages, liabilities or expenses are caused by an untrue statement or alleged
untrue statement or by an omission or alleged omission made in reliance upon and
in conformity with the written information so furnished by the Holder and stated
specifically for use in connection with the preparation of the registration
statement or prospectus; provided that the indemnity will not apply to the
extent that the loss, claim, damage, liability or expense arises out of or is
based upon a violation of this Agreement by the Company. If the offering
pursuant to any the registration is made through underwriters, each Holder
-13-
<PAGE>
agrees to enter into an underwriting agreement in customary form with the
underwriters and to indemnify the underwriters, their officers and directors, if
any, and each person or entity who controls the underwriters within the meaning
of the Securities Act to the same extent as hereinabove provided with respect to
indemnification by the Holder. Notwithstanding the foregoing or any other
provision of this Agreement, in no event will a Holder of Registrable Securities
be liable for any the losses, claims, damages, liabilities or expenses in excess
of the net proceeds received by the Holder in connection with its disposition of
Registrable Securities.
(c) Promptly after receipt by an indemnified party under Section 7.7 (a)
or (b) of notice of any claim as to which indemnity may be sought, including,
without limitation, the commencement of any action or proceeding, the
indemnified party will, if a claim in respect thereof may be made against the
indemnifying party under this Section, promptly notify the indemnifying party in
writing of the commencement thereof; provided that the failure of the
indemnified party so to notify the indemnifying party will not relieve the
indemnifying party from its obligations under this Section except to the extent
that the indemnifying party is adversely affected by the failure. In case any
action or proceeding is brought against any indemnified party, and it notifies
the indemnifying party of the commencement thereof, the indemnifying party and
its counsel will conduct the defense of any action with counsel approved by the
indemnified party (which approval will not be withheld or delayed unreasonably)
although the indemnified party will be entitled to participate therein, and
after notice from the indemnifying party to the indemnified party of its
election so to assume the defense thereof, the indemnifying party will not be
liable to the indemnified party under that Section for any legal or any other
expenses subsequently incurred by the indemnified party in connection with the
defense thereof (other than reasonable costs of investigation) unless incurred
at the written request of the indemnifying party. Notwithstanding the above, the
indemnified party will have the right to employ counsel of its own choice in any
action or proceeding (and be reimbursed by the indemnifying party for the
reasonable fees and expenses of the counsel and other reasonable costs of the
defense) if representation of the indemnified party by the counsel retained by
the indemnifying party would be inappropriate due to actual or potential
differing interests or conflicts between the indemnified party and any other
party represented by the counsel in the action or proceeding or counsel to the
indemnified party is of the opinion that it would not be desirable for the same
counsel to represent both the indemnifying party and the indemnified party
because the representation might result in a conflict of interest; provided,
however, that the indemnifying party will not in connection with any one action
or proceeding or separate but substantially similar actions or proceedings
arising out of the same general allegations, be liable for the reasonable fees
and expenses of more than one separate firm of attorneys at any time for all
indemnified parties, except to the extent that local counsel, in addition to
regular counsel, is required in order to effectively defend against the action
or proceeding. An indemnifying party will not be liable to any indemnified party
for any settlement or entry of judgment concerning any action or proceeding
effected without the consent of the indemnifying party.
(d) If the indemnification provided for in Section 7.7(a) or (b) is held
by a court of competent jurisdiction to be unavailable under applicable law to
an indemnified party in respect of any losses, claims, damages or liabilities
referred to therein, then each applicable indemnifying party, in lieu of
indemnifying the indemnified party, will contribute to the amount paid or
payable by the indemnified party as a result of the losses, claims, damages or
liabilities in the proportion as is appropriate to reflect the relative fault of
the Company on the one hand and of the indemnified party on the other in
connection with the statements or omissions which resulted in the losses,
claims, damages, or liabilities, as well as any other relevant equitable
considerations including the relative benefits to the parties. The relative
fault of the Company on the one hand and of the indemnified party on the other
will be determined by reference to, among other things, whether the untrue or
alleged untrue statement of a material fact or the omission to state a material
fact relates to information supplied by the Company or by the indemnified party
and the parties' relative intent, knowledge, access to information and
opportunity to correct or
-14-
<PAGE>
prevent the statement or omission. The amount paid or payable by a party as a
result of the losses, claims, damages and liabilities referred to above will be
deemed to include, subject to the limitations set forth in Section 7.7(c), any
legal or other fees or expenses reasonably incurred by the party in connection
with investigating or defending any action or claim. No person or entity guilty
of fraudulent misrepresentation (within the meaning of Section 11(f) of the
Securities Act) will be entitled to contribution from any person or entity that
is not guilty of fraudulent misrepresentation.
Section 8. Restrictions on Transfer.
(a) Notwithstanding anything to the contrary in Section 7, each Purchaser
agrees not to offer, pledge, sell, contract to sell, grant any option for the
sale of, or otherwise dispose of, directly or indirectly (any of which being a
"Transfer"), any Shares, Warrants or Conversion Shares except to an affiliate of
Purchaser that has agreed for the benefit of the Company to be bound by the
terms and conditions of this Agreement in a written instrument satisfactory in
form and substance to the Company and its counsel, during the date five days
prior to the Company's good faith estimate of the date of filing of, and ending
on a date 90 days after the effective date of, a Company-initiated underwritten
registration of equity securities of the Company; provided that the members of
the Board of Directors and executive officers of the Company are subject to an
agreement at least as restrictive as the foregoing.
(b) No Transfer in violation of this Agreement will be made or recorded on
the books of the Company and any Transfer or purported Transfer will be void ab
initio and of no force or effect. Upon request of the Company, each Purchaser
will certify in writing its compliance with this Section 8.
Section 9. Limitations on Purchasers' Ownership. No Purchaser nor any of
its affiliates (as defined in Rule 12b-2 under the Exchange Act) will directly
or indirectly without the prior written consent of the Board of Directors of the
Company acquire beneficial ownership within the meaning of Rule 13d-3 of the
Exchange Act (except by way of stock splits, stock dividends or similar events
affecting holders of securities of the Company generally) if the effect of the
acquisition would be to increase the aggregate voting power in the election of
Directors of the Company's Board of Directors of all securities of the Company
owned by Purchaser and the affiliates to more than 10% of the total combined
voting power of all securities of the Company then outstanding. No Purchaser or
any affiliate thereof will be required to dispose of any securities of the
Company if their aggregate percentage ownership is increased as a result of a
recapitalization of the Company.
Section 10. Miscellaneous.
10.1 Notices. Any notice or other communication given hereunder will be
deemed sufficient if in writing and sent by registered or certified mail, return
receipt requested, or delivered by hand against written receipt therefor,
addressed to:
-15-
<PAGE>
If to the Company:
AVAX Technologies, Inc.
4520 Main Street, Suite 930
Kansas City, MO 64111
Attn: Jeffrey M. Jonas, M.D.,
President and Chief Executive Officer
With a copy to:
Gilmore & Bell, P.C.
2405 Grand Boulevard, Suite 1100
Kansas City, MO 64108
Attn: Richard M. Wright
If to Purchasers:
To the names and addresses on Exhibit A.
Notices will be deemed to have been given or delivered on the date of
mailing, except notices of change of address, which will be deemed to have been
given or delivered when received.
10.2 Successors and Assigns. Subject to Section 7.6(i), this Agreement
will be binding upon and inure to the benefit of the parties hereto and to their
respective heirs, legal representatives, successors and assigns.
10.3 Entire Agreement; Survival of Representations and Warranties. This
Agreement sets forth the entire agreement and understanding among the parties as
to the subject matter hereof and merges and supersedes all prior discussions,
agreements and understandings of any and every nature among them; provided that
the Confidentiality Agreements between the Company and (i) each of the
Purchasers will survive. This Agreement may be amended only by mutual written
agreement of the Company and the Purchasers, and the Company may take any action
herein prohibited or omit to take any action herein required to be performed by
it, and any breach of any covenant, agreement, warranty or representation may be
waived, only if the Company has obtained the written consent or waiver of the
Purchasers. The representations and warranties of the Company set forth in this
Agreement will survive the Closing Date for 18 months notwithstanding any
earlier delivery and conversion of Shares or exercise of the Warrants except
that the representations and warranties set forth in Sections 6.2 and 6.3 will
survive indefinitely. The immediately preceding sentence will have no force or
effect on the obligations of the parties under this Agreement or any other
operative document relating to the transactions contemplated by this Agreement.
10.4 Governing Law; Consent to Jurisdiction; etc. (a) Notwithstanding the
place where this Agreement may be executed by any of the parties hereto, the
parties expressly agree that all the terms and provisions hereof will be
construed in accordance with and governed by the laws of the State of Delaware
without regard to that State's conflicts of law principles. In the event that a
judicial proceeding is necessary, the parties who are not citizens or residents
of the United States agree that the sole forum for resolving disputes arising
out of or relating to this agreement is any federal or state court in the State
of Missouri, and all related appellate courts (collectively, the "Courts"), and
each Purchaser irrevocably and unconditionally consents to the jurisdiction of
the Courts.
-16-
<PAGE>
(b) Each of the parties who are not citizens or residents of the United
States, irrevocably and unconditionally consents to venue in the Courts, and
irrevocably and unconditionally waives any objection to the laying of venue of
any judicial proceeding in the Courts, and agrees not to plead or claim in any
Court that any judicial proceeding brought in any court has been brought in an
inconvenient forum.
10.5 Severability. The holding of any provision of this Agreement to be
invalid or unenforceable by a court of competent jurisdiction will not affect
any other provision of this Agreement, which will remain in full force and
effect. If any provision of this Agreement is declared by a court of competent
jurisdiction to be invalid, illegal or incapable of being enforced in whole or
in part, the provision will be interpreted so as to remain enforceable to the
maximum extent permissible consistent with applicable law and the remaining
conditions and provisions or portions thereof will nevertheless remain in full
force and effect and enforceable to the extent they are valid, legal and
enforceable, and no provisions will be deemed dependent upon any other covenant
or provision unless so expressed herein.
10.6 No Waiver. A waiver by either party of a breach of any provision of
this Agreement will not operate, or be construed, as a waiver of any subsequent
breach by that same party.
10.7 Further Assurances. The parties agree to execute and deliver all
further documents, agreements and instruments and take further action as may be
necessary or appropriate to carry out the purposes and intent of this Agreement.
Any documentary, stamp tax or similar issuance or transfer taxes due as a result
of the conveyance, transfer or sale of the Shares and Warrants between any of
the Purchasers (or any of their permitted transferees), on the one hand, and the
Company, on the other hand, pursuant to this Agreement will be borne by the
Purchasers (or their respective permitted transferees).
10.8 Counterparts. This Agreement may be executed in two or more
counterparts, each of which will be deemed an original, but all of which will
together constitute the same instrument.
10.9 No Third Party Beneficiaries. Nothing in this Agreement creates in
any person not a party to this Agreement any legal or equitable right, remedy or
claim under this Agreement, and this Agreement is for the exclusive benefit of
the parties hereto. The parties expressly recognize that this Agreement is not
intended to create a partnership, joint venture or other similar arrangement
between any of the parties or their respective affiliates.
10.10 Publicity Restrictions. No press release or other public disclosure
relating to the transactions contemplated by this Agreement may be issued or
made by or on behalf of any Purchaser without prior consultation with the
Company, except as required by applicable law, court process or stock exchange
rules, in which case the Purchaser required to make the disclosure will allow
the Company reasonable time (to the extent practicable) to comment thereon in
advance of the issuance.
-17-
EXHIBIT 99.1
FOR IMMEDIATE RELEASE
Company Contacts: Jeffrey Jonas, Chief Executive Officer
Richard Rainey, Controller
AVAX Technologies, Inc.
(816) 960-1333
Investors: Olga Fleming/Sue Yeoh
CPR Financial Communications
(201) 641-2408
AVAX TECHNOLOGIES COMPLETES $25 MILLION INSTITUTIONAL PRIVATE PLACEMENT
KANSAS CITY, MISSOURI -- MARCH 13, 2000 - AVAX TECHNOLOGIES, INC. ("AVAX")
(Nasdaq: AVXT) today announced that it has completed a private placement of
common stock and warrants with institutional investors for a total consideration
of $25.1 million. New York-based investment bank Gruntal & Co., L.L.C. acted as
placement agent.
The private placement consisted of 2,259,494 million newly issued shares of
common stock priced at $11.125 per share and warrants to purchase an additional
225,951 shares of common stock. The warrants can be exercised at a price of
$12.79 per common share, or 115% of the offering price. The warrants will expire
on March 10, 2005. Net proceeds from the offering are approximately $24.2
million and will be used to fund clinical trials of AVAX's lead product
candidates, M-Vax(TM) for the treatment of Stage III melanoma and O-Vax(TM) for
the treatment of late-stage ovarian cancer and for general working capital
purposes.
Jeffrey M. Jonas, President and Chief Executive Officer of AVAX Technologies,
stated, "This financing is an important component of our corporate agenda,
helping us to continue the clinical process in the U.S. and to prepare for the
commercialization of M-Vax in international markets. With this additional
funding, we plan to advance our development programs here in the U.S, which
include a pivotal registration trial for M-Vax and a multi-center Phase 2 trial
of O-Vax, as well as other trials we hope to initiate later this year. We have
set aggressive milestones for 2000 and will utilize this additional capital to
continue investigating and validating the promise of our autologous cancer
vaccine technology."
AVAX Technologies, Inc. specializes in the development and commercialization of
novel biotechnologies, immunotherapies and pharmaceuticals for cancer and other
life-threatening diseases using three core technologies: autologous cell (AC)
vaccines, topoisomerase inhibitors and anti-estrogens.
Except for statements that are historical, the statements in this release are
"forward-looking" statements that are made pursuant to the safe harbor
provisions of Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934. Forward-looking statements involve significant
risks and uncertainties, and in light of the significant uncertainties inherent
in such statements, the inclusion of such information should not be regarded as
a representation by AVAX that the objectives and plans of the company will be
achieved. In fact, actual results could differ materially from those
contemplated by such forward-looking statements. Many important factors affect
the company's ability to achieve the stated outcomes and to develop successfully
and commercialize its product candidates, including, the ability to obtain
substantial additional funds, to obtain and maintain all necessary patents or
licenses, to demonstrate the safety and efficacy of product candidates at each
stage of development, to meet applicable regulatory standards and receive
required regulatory approvals, to meet obligations and required milestones under
its license agreements, to be capable of producing drug candidates in commercial
quantities at reasonable costs, to compete successfully against other products,
and to market products in a profitable manner, as well as other risks detailed
from time to time in AVAX's public disclosure filings with the Securities and
Exchange Commission, including its Annual Report on Form 10-KSB for the year
ended December 31,1999. AVAX does not undertake any obligation to release
publicly any revisions to these forward-looking statements or to reflect the
occurrence of unanticipated events.
# # #
